Review: Diabetic dyslipidaemia — the case for using statins

Abstract

Type 2 diabetes is associated with an increased risk of coronary heart disease (CHD). The association between CHD and abnormal plasma lipid levels has led current guidelines to recommend pharmacological modification of the lipid profile. Statins are particularly effective at reducing cholesterol levels, with additional benefits on other components of the lipid profile. Lipid-modifying therapy should be used routinely to reduce the risk of CHD in patients with type 2 diabetes.

Keywords

cardiovascular disease coronary heart disease dyslipidaemia statins type 2 diabetes.

Get full access to this article

View all access options for this article.

References

King H. , Aubert RE , Herman WH Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.

Haffner SM , Lehto S. , Ronnemaa T. , Pyörälä K. , Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

Syvänne M. , Taskinen MR Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997;350(suppl I):20-3.

Reaven GM Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-86.

Ford ES , Giles WH , Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.

European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999;16:716-30.

Freeman DJ , Norrie J. , Satter N. et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.

Khaleeli E. , Peters SR , Bobrowsky K. , Oudiz RJ , Ko JY , Budoff MJ Diabetes 44.

10.

Turner RC , Millns H. , Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.

11.

Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes . Diabetes Care 1995;18:258-68.

12.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

13.

Shepherd J. , Cobbe SM , Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-07.

14.

Downs JR , Clearfield M. , Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.

15.

Sacks FM , Pfeffer MA , Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-09.

16.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.

17.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.

18.

Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.

19.

National Service Framework for Coronary Heart Disease. 2000; Department of Health, London.

20.

Wood D. , De Backer G. , Faergeman O. , Graham I. , Mancia G. , Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.

21.

American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2002;25(suppl 1):S74-S77.

22.

Keidan B. , Hsia J. , Katz R. Plasma lipids and antidiabetic agents: a brief overview. Br J Diabetes Vasc Dis 2002;2:40-3.

23.

Jones P. , Kafonek K. , Laurora I. , Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.

24.

Olsson AG , McTaggart F. , Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28.

25.

Nestel PJ Adulthood - treatment: cholesterol-lowering with plant sterols. Med J Aust 2002;176(11 suppl):S122.

26.

Matvienko OA , Lewis DS , Swanson M. et al. A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am J Clin Nutr 2002;76:57-64.

27.

Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J Supplements 2001;3(suppl E):E11-16.

28.

Knopp RH , Gitter H. , Truitt T. et al. Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis Suppl 2001;2:38.

29.

Pyörälä K. , Pederson TR , Kjekshus J. , Faergeman O. , Olsson AG , Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.

30.

Sacks FM , Tonkin AM , Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Investigators Group. Circulation 2000;102:1893-900.

31.

Velussi M. , Cernigoi AM , Tortul C. , Merni M. Atorvastatin for the management of type 2 diabetic patients with dyslipidaemia . A mid-term (9 months) treatment experience. Diabetes Nutr Metab 1999;12:407-12.

32.

Aguilar-Salinas CA , Gómez-Pérez FJ , Posadas-Romero C. et al. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Atherosclerosis 2000;152:48996.

33.

Sheu Wh-H , Jeng C-Y. , Lee W-J. , Lin S-Y. , Pei D. , Chen Y-T. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism 2001;50:355-9.

34.

Sever PS , Dahlof B. , Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations , in the AngloScandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.

35.

Liao J. Beyond lipid lowering: the role of statins in vascular protection . Int J Cardiol 2002;86:5-18.

36.

Bellosta S. , Ferri N. , Arnaboldi L. , Bernini F. , Paoletti R. , Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23(suppl 2):B72-78.

37.

Murdock DK , Murdock AK , Murdock RW et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999;138:151-5.

38.

Papadakis JA , Ganotakis ES , Jagroop IA , Winder AF , Mikhailidis DP Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease . Int J Cardiol 1999;69:237-44.

39.

Spieker LE , Noll G. , Hannak M. , Luscher TF Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharmacol 2000;35:361-5.

40.

Gavish D. , Leibovitz E. , Shapira I. , Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000;247:563-9.

41.

Durrington P. , Tuomilehto J. , Hamann A. , Southworth H. , Pears J. , Kallend D. Effects of rosuvastatin alone and in combination with fenofibrate on lipid subfractions in patients with type 2 diabetes: results at 24 weeks. Circulation 2001;104(suppl):II-856.

42.

Furberg CD , Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-07.

43.

Shek A. , Ferrill MJ Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17.

44.

Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995;16:5-13.

45.

Euroaspire II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22:554-72.

46.

Pearson TA , Laurora I. , Chu H. , Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.

47.

Shepherd J. , Hunninghake DB , Barter P. , McKenney J. , Hutchinson H. Guidelines for lowering lipids to reduce coronary heart disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91 (suppl):11C-9C.

48.

Andrews T. , Ballantyne CM , Hsia J. , Kramer J. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-91.

49.

The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and lowdose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.

50.

Pitt B. , Waters D. , Brown WV et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341: 70-6.

51.

Schwartz GG , Olsson AG , Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. JAMA 2001;285:1711-18.

52.

Brown J. , Pedula K. , Bakst A. The progressive cost of complications in type 2 diabetes mellitus . Arch Intern Med 1999;159:1873-80.

53.

Maclaine GD , Patel H. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels. Int J Clin Pract 2001;55:243-9.

54.

Grover SA , Ho V. , Lavoie F. , Coupal L. , Zowall H. , Pilote L.

The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?

Arch Intern Med 2003;163:333-9.

55.

Jonsson B. , Cook JR , Pedersen TR The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999 ; 42:1293-301.

56.

Grover SA , Coupal L. , Zowall H. , Alexander CM , Weiss TW , Gomes DR

How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?

Diabetes Care 2001;24:45-50.

57.

Hay JW , Yu WM , Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999;15:47-74.